Table 4.
Changes in laboratory parameters in surviving patients (n = 7).
| Laboratory parameter | At initiation of ECZ | At discontinuation of ECZ | Pa | Last observation | Pa | |||
|---|---|---|---|---|---|---|---|---|
| PLT count, ×109/L | 32 | (14–43) | 58 | (38–164) | 0.073 | 186 | (106–258) | 0.011 |
| LDH, U/L | 652 | (509-808) | 283 | (224–322) | <0.01 | 232 | (198–261) | <0.01 |
| sCr, mg/dL | 0.49 | (0.26-0.89) | 0.37 | (0.28–0.61) | 0.79 | 0.39 | (0.36–0.65) | 0.79 |
Values are median (IQR).
ECZ eculizumab, eGFR estimated glomerular filtration rate, LDH lactate dehydrogenase, PLT platelet, sCr serum creatinine.
aP-values versus at the initiation of eculizumab.